دورية أكاديمية
Does Changing Inhaler Device Impact Real-Life Asthma Outcomes? Clinical and Economic Evaluation
| العنوان: | Does Changing Inhaler Device Impact Real-Life Asthma Outcomes? Clinical and Economic Evaluation |
|---|---|
| المؤلفون: | Rhee, Chin Kook, van Boven, Job F M, Yau Ming, Simon Wan, Park, Hye Yun, Kim, Deog Kyeom, Park, Hae-Sim, Zhi Jie, Joanna Ling, Yoo, Kwang-Ha, Price, David B |
| المصدر: | Rhee , C K , van Boven , J F M , Yau Ming , S W , Park , H Y , Kim , D K , Park , H-S , Zhi Jie , J L , Yoo , K-H & Price , D B 2019 , ' Does Changing Inhaler Device Impact Real-Life Asthma Outcomes? Clinical and Economic Evaluation ' , The Journal of Allergy and Clinical Immunology: In Practice , vol. 7 , no. 3 , pp. 934-942 . https://doi.org/10.1016/j.jaip.2018.09.027Test |
| سنة النشر: | 2019 |
| المجموعة: | University of Groningen research database |
| مصطلحات موضوعية: | Asthma, Cost-effectiveness, Dry powder inhaler, Economic evaluation, Inhaler, Pressurized metered-dose inhaler, metered dose inhaler, beclometasone, budesonide plus formoterol, fluticasone propionate plus formoterol fumarate, fluticasone propionate plus salmeterol, formoterol, acute respiratory tract disease, adolescent, adult, aged, article, child, clinical effectiveness, clinical evaluation, cohort analysis, cost effectiveness analysis, disease course, disease severity, female, health care cost, human, major clinical study, male, retrospective study |
| الوصف: | BACKGROUND: Inhaler usability and deposition differ between devices. Change of device may therefore have an impact on clinical and economic outcomes. OBJECTIVE: To characterize clinical and economic asthma outcomes surrounding the change from a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) for fixed-dose combination inhaled corticosteroid/long-acting β agonist (FDC ICS/LABA) treatment. METHODS: Three retrospective cohort substudies using 2010 to 2015 data from the Korean Health Insurance and Review Assessment Service database were performed. Patients with asthma who received an FDC ICS/LABA pMDI for the first time after initially being on FDC ICS/LABA DPI were included. The following outcomes were assessed: (1) persistence of change to pMDI over 6 months, (2) clinical outcomes during the year after the change compared with the baseline year; and (3) noninferiority comparison of costs and effectiveness between patients changing to a pMDI and matched patients who continued their DPI. RESULTS: Patients who change inhalers seem to represent a more severe subpopulation. Fifty-eight percent of patients (95% CI, 56-60) persisted with the change. After the change in therapy, an increased proportion of patients (58.3%) remained free from severe exacerbations compared with the year before (47.4%; P < .001). Patients who changed to pMDIs had significantly less severe exacerbations, acute respiratory events, and lower short-acting β agonist inhaler average daily dose, but higher average ICS daily dose (all P < .05), compared with matched patients remaining on a DPI. Total costs were similar between patients who changed to pMDI therapy compared with those remaining on a DPI. CONCLUSION: Changing from a DPI to a pMDI for FDC ICS/LABA asthma treatment can be as effective and cost-effective as remaining on a DPI. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://research.rug.nl/en/publications/2542ea6e-4f1a-4388-86d0-b1eeaaed157aTest |
| DOI: | 10.1016/j.jaip.2018.09.027 |
| الإتاحة: | https://doi.org/10.1016/j.jaip.2018.09.027Test https://hdl.handle.net/11370/2542ea6e-4f1a-4388-86d0-b1eeaaed157aTest https://research.rug.nl/en/publications/2542ea6e-4f1a-4388-86d0-b1eeaaed157aTest https://pure.rug.nl/ws/files/80567962/1_s2.0_S2213219818306044_main.pdfTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.7C72FC57 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.jaip.2018.09.027 |
|---|